Literature DB >> 27989641

Targeting Vascular Remodeling to Treat Pulmonary Arterial Hypertension.

A A Roger Thompson1, Allan Lawrie2.   

Abstract

Pulmonary arterial hypertension (PAH) describes a group of conditions with a common hemodynamic phenotype of increased pulmonary artery pressure, driven by progressive remodeling of small pulmonary arteries, leading to right heart failure and death. Vascular remodeling is the key pathological feature of PAH, but treatments targeting this process are lacking. In this review, we summarize important advances in our understanding of PAH pathogenesis from novel genetic and epigenetic factors, to cell metabolism and DNA damage. We show how these processes may integrate and highlight exploitable targets that could alter the relentless vascular remodeling in PAH.
Copyright © 2016 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  BMPR2; hypoxia; miRNA; pulmonary hypertension; vascular remodeling

Mesh:

Substances:

Year:  2016        PMID: 27989641     DOI: 10.1016/j.molmed.2016.11.005

Source DB:  PubMed          Journal:  Trends Mol Med        ISSN: 1471-4914            Impact factor:   11.951


  52 in total

Review 1.  Drug abuse and HIV-related pulmonary hypertension: double hit injury.

Authors:  Zachery J Harter; Stuti Agarwal; Pranjali Dalvi; Norbert F Voelkel; Navneet K Dhillon
Journal:  AIDS       Date:  2018-11-28       Impact factor: 4.177

Review 2.  Vascular Metabolic Mechanisms of Pulmonary Hypertension.

Authors:  Xiao-Fan Shi; Yun-Chao Su
Journal:  Curr Med Sci       Date:  2020-07-17

3.  Endothelial and Smooth Muscle Cell Interaction via FoxM1 Signaling Mediates Vascular Remodeling and Pulmonary Hypertension.

Authors:  Zhiyu Dai; Maggie M Zhu; Yi Peng; Hua Jin; Narsa Machireddy; Zhijian Qian; Xianming Zhang; You-Yang Zhao
Journal:  Am J Respir Crit Care Med       Date:  2018-09-15       Impact factor: 21.405

Review 4.  Critical effects of epigenetic regulation in pulmonary arterial hypertension.

Authors:  Dewei Chen; Wenxiang Gao; Shouxian Wang; Bing Ni; Yuqi Gao
Journal:  Cell Mol Life Sci       Date:  2017-06-01       Impact factor: 9.261

5.  A wrinkle in time: circadian biology in pulmonary vascular health and disease.

Authors:  Andrew J Bryant; Elnaz Ebrahimi; Amy Nguyen; Christopher A Wolff; Michelle L Gumz; Andrew C Liu; Karyn A Esser
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2021-12-01       Impact factor: 5.464

6.  Paclitaxel alleviates monocrotaline-induced pulmonary arterial hypertension via inhibition of FoxO1-mediated autophagy.

Authors:  Wei Feng; Jian Wang; Xin Yan; Cui Zhai; Wenhua Shi; Qingting Wang; Qianqian Zhang; Manxiang Li
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2019-01-25       Impact factor: 3.000

7.  Docetaxel Reverses Pulmonary Vascular Remodeling by Decreasing Autophagy and Resolves Right Ventricular Fibrosis.

Authors:  Yasmine F Ibrahim; Nataliia V Shults; Vladyslava Rybka; Yuichiro J Suzuki
Journal:  J Pharmacol Exp Ther       Date:  2017-07-31       Impact factor: 4.030

Review 8.  MiRNAs, lncRNAs, and circular RNAs as mediators in hypertension-related vascular smooth muscle cell dysfunction.

Authors:  Ji-Ru Zhang; Hai-Jian Sun
Journal:  Hypertens Res       Date:  2020-09-23       Impact factor: 3.872

9.  TRIM32 inhibits the proliferation and migration of pulmonary artery smooth muscle cells through the inactivation of PI3K/Akt pathway in pulmonary arterial hypertension.

Authors:  Zhi Hu; Qiang Song; Hui Ma; Yaozhang Guo; Tingting Zhang; Hang Xie; Xiaohui Luo
Journal:  J Bioenerg Biomembr       Date:  2021-03-10       Impact factor: 2.945

10.  Regulation of the Methylation and Expression Levels of the BMPR2 Gene by SIN3a as a Novel Therapeutic Mechanism in Pulmonary Arterial Hypertension.

Authors:  Malik Bisserier; Prabhu Mathiyalagan; Shihong Zhang; Firas Elmastour; Peter Dorfmüller; Marc Humbert; Gregory David; Sima Tarzami; Thomas Weber; Frederic Perros; Yassine Sassi; Susmita Sahoo; Lahouaria Hadri
Journal:  Circulation       Date:  2021-06-03       Impact factor: 39.918

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.